英文互译镜像站

Artesunate/amodiaquine

Last updated
Artesunate/amodiaquine
Combination of
Artesunate Antimalarial
Amodiaquine Antimalarial
Clinical data
Trade names Camoquin, others [1]
Other namesASAQ
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria. [2] [3] It is a fixed-dose combination of artesunate and amodiaquine. [2] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria. [4] It is taken by mouth. [3]

Contents

Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough. [5] Safety in pregnancy is not clear; however, the medication may be used if others are not possible. [5] It is believed to be safe for use during breastfeeding. [5] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms. [5]

Artesunate/amodiaquine was commercially launched in 2007. [6] It is on the World Health Organization's List of Essential Medicines. [2] Artesunate/amodiaquine is available as a generic medication. [6] As of 2014 it is not commercially available in the United States or United Kingdom. [1] [7]

Medical uses

Early clinical trials showed that a once-a-day dosage was effective. [8] It was subsequently clinically shown to be equally effective as artemether/lumefantrine, [9] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

Society and culture

Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis. [6] ASAQ was handed over to the MMV Access and Product Management Team in May 2015. [10]

References

  1. 1 2 Ainsworth SB (2014). "Amodiaquine with artesunate". Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN   978-1-118-81951-7. Archived from the original on 2016-12-20.
  2. 1 2 3 World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  3. 1 2 Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. (March 2007). "Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children". Malaria Journal. 6 29. doi: 10.1186/1475-2875-6-29 . PMC   1831475 . PMID   17352806.
  4. ↑ Stuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary 2008. World Health Organization. p. 187. hdl: 10665/44053 . ISBN   978-92-4-154765-9.
  5. 1 2 3 4 "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
  6. 1 2 3 "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
  7. ↑ Rosenthal PJ, Kamya M (2015). "Malaria". In Goldman L, Schafer AI (eds.). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN   978-0-323-32285-0. Archived from the original on 2016-12-20.
  8. ↑ Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8 125. doi: 10.1186/1475-2875-8-125 . PMC   2698916 . PMID   19505304.
  9. ↑ Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, et al. (August 2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10 237. doi: 10.1186/1475-2875-10-237 . PMC   3171378 . PMID   21838909.
  10. ↑ "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. 22 May 2015. Retrieved 2020-02-13.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
泛镜像站群 干扰字符镜像 英文互译镜像站 泛目录+镜像 镜像站群霸屏